HighMark Wealth Management’s Neuropace NPCE Stock Holding History

HighMark Wealth Management’s Portfolio NPCE Stock Details NPCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.59M	Buy	163,000 +100,000	+159%	+$1.61M	0.87%	20
2026 Q1	$828K	Hold	63,000	–	–	0.34%	37
2025 Q4	$973K	Hold	63,000	–	–	0.4%	36
2025 Q3	$650K	Hold	63,000	–	–	0.29%	43
2025 Q2	$702K	Buy	63,000 +60,000	+2,000%	+$750K	0.34%	40
2025 Q1	$36.9K	Hold	3,000	–	–	0.02%	151
2024 Q4	$33.6K	Hold	3,000	–	–	0.02%	159
2024 Q3	$20.9K	Buy	+3,000	New	+$21.9K	0.01%	202

Other funds holding NPCE

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

HighMark Wealth Management's NPCE Position: Q2 2026 in Review

HighMark Wealth Management increased its Neuropace (NPCE) stake by 159% in Q2 2026, buying an estimated $1.61M and bringing the position to 163,000 shares worth $2.59M. The position accounts for 0.87% of the portfolio, ranked #20.

HighMark Wealth Management first reported a position in NPCE in Q3 2024 and has held it in 8 quarters since. 112 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

HighMark Wealth Management held 163,000 shares of Neuropace worth $2.59M as of Q2 2026.
HighMark Wealth Management bought 100,000 Neuropace shares in Q2 2026, an estimated $1.61M.
Neuropace made up 0.87% of HighMark Wealth Management's portfolio in Q2 2026, its #20 holding.
HighMark Wealth Management first reported a position in Neuropace in Q3 2024 and has held it in 8 quarters since.
112 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on HighMark Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.